Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
05 November 2020 | Story Thabo Kessah | Photo Thabo Kessah
Prof Geofrey Mukwada says funding from the US Embassy and Consulates in South Africa will reinforce the ARU mandate.

The University of the Free State (UFS) will further strengthen its ties with the Appalachian State University in the next two academic years through a mountain-to-mountain research project funded by the US Embassy and Consulates in South Africa.

The R8 million project between the UFS and the US institution will cover the two master’s degree programmes in underdeveloped niche areas, meteorological weather stations, leadership capacity building for black women in academia, and doctoral research projects. Qwaqwa Campus departments that will be involved are Physics, Geography, Community Development, and the ARU.

Talking about this collaboration, the project leader, Prof Geofrey Mukwada, said it would bring together researchers from both the UFS and Appalachian State University and enable them to work together to develop what is currently an underdeveloped research niche, i.e. mountain studies. 

“This project will reinforce the mandate of the Afromontane Research Unit (ARU). It will provide the basis for a long-term development agenda through training and infrastructure development. For instance, the project will fund the implementation of two master’s degree programmes – the MSc in Mountain Environments and the MA in Community Development – which are long-term projects,” he said. 

“It will also support innovation in climate change research. Through this project, it will be possible to receive climate data from weather stations that are situated in distant, isolated, and generally inaccessible locations without travelling to those locations. We will be able to understand how the climate of the region is changing and assist in developing adaptation measures and decisions that are applicable to agriculture, water, tourism, environment, and other sectors. This will enhance the capacity of the ARU to contribute to the development of research in mountain environments,” he added. 

There will be a virtual launch of the project on Tuesday 10 November 2020 at 15:00 (CAT).

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept